CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION

被引:39
|
作者
BROSEN, K [1 ]
NIELSEN, PN [1 ]
BRUSGAARD, K [1 ]
GRAM, LF [1 ]
SKJODT, K [1 ]
机构
[1] ODENSE UNIV,INST MED BIOL,DEPT MED MICROBIOL,DK-5000 ODENSE,DENMARK
关键词
SPARTEINE-OXIDATION; GENETIC POLYMORPHISM; CYP2D6; GENOTYPING; XBA1; RFLP-PCR; DANISH POPULATION;
D O I
10.1007/BF02570501
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, DG-wt. However, the DG-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the DG-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11-4.10) and the corresponding value in heterozygous EM was 0.36 (0.11-9.10). The median difference was 0.09 (95% confidence interval: 0.02-0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 50 条
  • [31] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [32] CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele
    Gaedigk, Andrea
    Riffel, Amanda K.
    Leeder, J. Steven
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 740 - 748
  • [33] Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6
    Masimirembwa, C
    Hasler, J
    Bertilssons, L
    Johansson, I
    Ekberg, O
    IngelmanSundberg, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (02) : 117 - 122
  • [34] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [35] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [36] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [37] Estimating genotype and allele frequencies of the CYP2D6 gene
    Acuna, M.
    Eaton, Y. L.
    PHARMACOLOGICAL RESEARCH, 2016, 110 : 240 - 240
  • [38] CYP2D6 HhaI genotype and the neuroleptic malignant syndrome
    Iwahashi, K
    Yoshihara, E
    Nakamura, K
    Ameno, K
    Watanabe, M
    Tsuneoka, Y
    Ichikawa, Y
    Igarashi, K
    NEUROPSYCHOBIOLOGY, 1999, 39 (01) : 33 - 37
  • [39] Effect of genotype and methylation of CYP2D6 on smoking behaviour
    Tiili, Emmi M.
    Antikainen, Miia S. H.
    Mitiushkina, Natalia V.
    Sukhovskaya, Olga A.
    Imyanitov, Evgeny N.
    Hirvonen, Ari P.
    PHARMACOGENETICS AND GENOMICS, 2015, 25 (11): : 531 - 540
  • [40] Effect of CYP2D6 genotype on duloxetine serum concentration
    Hole, Kristine
    Gangso, Sofie
    Jensstuen, Asa Tonette
    Ormoy, Hanne Holte
    Paulsen, Maren
    Molden, Espen
    Haslemo, Tore
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (01) : 186 - 192